Welcome to our dedicated page for Mind Medicine SEC filings (Ticker: MNMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Definium Therapeutics, Inc. filings document regulatory disclosures for a British Columbia late-stage clinical biopharmaceutical company developing therapeutics for psychiatric and neurological disorders. Recent Form 8-K reports furnish operating results and corporate highlights and file clinical and commercial updates for DT120 ODT (lysergide tartrate), including programs in major depressive disorder, generalized anxiety disorder and posttraumatic stress disorder.
Proxy materials cover annual meeting matters such as director elections, auditor appointment and governance proposals. The filing record also reflects capital resources, research-and-development priorities, exhibit filings, shareholder voting mechanics and Nasdaq public-company governance for the issuer.
Mark Sullivan reports intent to sell 10,702 shares of Common Stock on 03/25/2026. The filing lists the shares as restricted stock vesting under a registered plan and identifies the transaction as involving the issuer. The filing also discloses a prior sale of 11,276 shares on 12/26/2025.
Definium Therapeutics reported a larger full-year 2025 net loss of $183.8 million, compared with $108.7 million in 2024, as it ramped late-stage development for its psychedelic-based therapies.
Cash, cash equivalents and investments rose to $411.6 million as of December 31, 2025, up from $273.7 million a year earlier, helped by a $259 million equity financing completed in the fourth quarter. The company expects this cash to fund operations into 2028.
Research and development expenses increased to $117.7 million from $65.3 million, driven mainly by higher DT120 program spending and expanded R&D staffing. General and administrative costs rose to $48.6 million from $38.6 million, reflecting greater professional services, pre-commercial efforts, and personnel expenses.
Definium highlighted progress across four Phase 3 trials of DT120 ODT in major depressive disorder and generalized anxiety disorder, with its Emerge MDD study fully enrolled and multiple topline readouts anticipated in 2026. It also advanced DT402 into a Phase 2a study for autism spectrum disorder.
Definium Therapeutics, Inc. has a large shareholder group led by Commodore Capital LP reporting beneficial ownership of 7,428,775 common shares, representing 7.2% of the company as of December 31, 2025. This position includes 2,000,000 common shares plus 5,428,775 shares that can be acquired through a pre-funded warrant, which is subject to a 9.99% beneficial ownership limitation. The ownership percentage is based on 98,509,279 common shares reported outstanding as of October 31, 2025, plus the warrant shares. The filing is made jointly by Commodore Capital LP, Commodore Capital Master LP, and managing partners Robert Egen Atkinson and Michael Kramarz, who certify that the securities are not held for the purpose of changing or influencing control of the issuer. The issuer recently changed its name from Mind Medicine (MindMed) Inc. to Definium Therapeutics, Inc.
Driehaus Capital Management LLC, a Delaware investment adviser, reported beneficial ownership of Definium Therapeutics, Inc. common stock. Driehaus has shared voting and dispositive power over 6,537,202 shares, representing 6.64% of the company’s common stock as of the event date.
The shares are held in numerous fully discretionary client accounts managed by Driehaus, which reports potential voting and dispositive power, while clients generally do not hold more than 5% of the class individually. Driehaus states the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Definium Therapeutics.
Avoro Capital Advisors LLC and Behzad Aghazadeh have reported a new significant ownership position in Definium Therapeutics, Inc. They beneficially own 5,000,000 Common Shares, representing 5.08% of the class, with sole voting and dispositive power over these shares.
The ownership percentage is based on 98,509,279 Common Shares outstanding as of October 31, 2025, as referenced from the company’s Form 10-Q for the quarter ended September 30, 2025. The investors state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Definium Therapeutics, Inc. received an amended Schedule 13G from Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin reporting a significant ownership position. The group reports beneficial ownership of 5,676,540 common shares, representing 5.54% of the class as of December 31, 2025.
This total includes 4,000,000 pre-funded warrants exercisable into common shares, calculated against 102,509,279 shares (98,509,279 shares outstanding as of October 31, 2025 plus the warrant shares). The warrants are subject to a 9.99% Maximum Percentage cap on post-exercise ownership, limiting how many can be exercised at any time.
The reporting persons state that the securities were not acquired to change or influence control, indicating a passive investment intent under the relevant SEC rules.
Definium Therapeutics director Roger Adsett received a grant of stock options on 01/29/2026. The award covers options to buy 50,000 common shares at an exercise price of $17.24 per share, all held directly.
The options vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in 24 equal monthly installments, contingent on Mr. Adsett’s continued service to the company.
Definium Therapeutics, Inc. reported a change to its board of directors. On January 28, 2026, the board expanded from six to seven members and appointed Roger Adsett as a director effective January 29, 2026, with a term running until the 2026 annual general meeting, or until a successor is chosen or he departs earlier.
Adsett was not assigned to any board committees at this time. Under the company’s non-employee director compensation policy, he will receive an annual cash retainer of $40,000, paid quarterly on a pro-rata basis. He also received an option to purchase 50,000 common shares, vesting one-third on the first anniversary of the grant date and the remainder in equal monthly installments thereafter, subject to continued board service.
The option grant was issued under the company’s 2025 Equity Incentive Plan. The filing notes there are no special arrangements leading to his appointment and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., reported estimated preliminary cash, cash equivalents and investments of about $412 million as of December 31, 2025, shared in a corporate presentation posted online. This figure is unaudited, may change, and has not been reviewed or examined by KPMG LLP.
The company has officially changed its corporate name to Definium Therapeutics, Inc., with board approval and updated British Columbia corporate records. The rebranding is described as aligning with its next phase as a psychiatric drug development leader. Common shares will keep the same CUSIP and begin trading on the Nasdaq under the new ticker “DFTX” starting January 13, 2026, with no action required from shareholders.
Mind Medicine (MindMed) Inc. (MNMD) reported Q3 results and liquidity updates. The company recorded a net loss of $67.3 million for the quarter, driven by operating expenses of $45.7 million (research and development $31.0 million; general and administrative $14.7 million) and a $22.5 million non-cash loss from the change in fair value of 2022 USD Financing Warrants. Basic and diluted net loss per share were $0.78.
As of September 30, 2025, cash and cash equivalents were $19.96 million and short-term investments were $189.11 million. Total assets were $236.9 million against total liabilities of $106.3 million, resulting in shareholders’ equity of $130.6 million. Common shares outstanding were 76,774,057 as of quarter-end; 98,509,279 were outstanding as of October 31, 2025.
Subsequent to quarter-end, on October 31, 2025, the company closed an underwritten public offering for gross proceeds of $258.9 million (net $242.8 million) to fund product development and general purposes. Earlier in 2025, MindMed amended its K2 HealthVentures credit facility, funded $42.0 million in a first tranche, and saw $1.0 million converted into 249,377 common shares.